Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sodium Oligomannate (GV-971) Safety and Efficacy in the Treatment of Alzheimer's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Aging, Dementia, Cognitive, and Behavioral Neurology
P11 - Poster Session 11 (5:30 PM-6:30 PM)
9-005
Alzheimer's disease (AD) debilitates cognitive function, posing a significant global health burden. The amyloid hypothesis underscores Aβ protein imbalance. Sodium oligomannate (GV-971), derived from marine sources, shows potential in animal models by inhibiting Aβ deposition and neuroinflammation. Further research aims to validate its therapeutic efficacy.

This meta-analysis aims at evaluating the safety and efficacy of sodium oligomannate in treating Alzheimer’s disease based on data from randomized controlled trials.

We have Searched four electronic databases; PubMed, Scopus, WOS, Cochrane to determine related published studies through 1 March 2023 until 1 April 2023 were searched for randomized controlled trials (RCTs) comparing GV-971 and Placebo as a potential treatment for patients with Al-Zahiemer disease. This Meta-analysis was conducted to explore the response to Assessment Scale-Cognitive Subscale 12 (ADAS-COG12), Alzheimer’s Disease Cooperative Study–Activities of Daily Living Scale (ADCS-ADL), Neuropsychiatric inventory (NPI) and its safety with possible adverse effects.
A total of 1108 patients of three RCTs were included. Pooled estimate of included studies for the ADAS-COG12, sodium oligomannate was preferred to placebo (MD= -2.72, 95% CI (-5.43, -0.02), p = 0.05). However, Pooled analysis for the ADCS-ADL and NPI did not favor either of the two groups (MD=1.80, 95% CI (-2.29, -5.89), p= 0.39) and (MD=-3.41, 95% CI (-12.26, 5.43), p= 0.45), respectively.
According to data presented in this meta-analysis, GV-971 has clear advantages over placebo in improving ADAS-COG12 of Alzheimer's disease. In terms of efficacy, GV-971 is shown to be similarly beneficial in treating Alzheimer's disease as donepezil. This meta-analysis supports the good safety profile and tolerance of sodium oligomannate (GV-971) in Alzheimer's disease patients.
Authors/Disclosures
Amr Elrosasy
PRESENTER
No disclosure on file
Mohamed Abo Zeid No disclosure on file
Ahmed S. Negida, MD, PhD (Virginia Commonwealth University) Dr. Negida has nothing to disclose.